 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| PSID Launches Robust New Site and CNAB Powerful New Partners |
|
 Hot Stock to Watch
|
Company: PositiveID Corporation (OTCQB: PSID)
|
End of Day:
Price: 0.0257
Change (%): - 0.0016 (5.86)
Volume: 1,165,935 |
 |
PositiveID Corporation Launches New Website at www.psidcorp.com
DELRAY BEACH, Fla., Feb. 25, 2015 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has launched a new corporate website at www.psidcorp.com.
PositiveID’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) continuously and autonomously analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins for up to 30 days. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up-to-date status of field conditions. M-BAND is the only system of its kind successfully demonstrated in the field under the DHS’ BAND Program (Bio-agent Autonomous Networked Detector).
Continue Reading
|
 Yesterday's Top Performer
|
Company: BioCorRx Inc. (OTCQB: BICX)
|
End of Day:
Price: 0.06
Change (%): + 0.003 (5.26)
Volume: 602,163 |
 |
About BioCorRx, Inc.
BioCorRx, Inc. ® (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program® consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program.
Company Information Sheet |
SmallCapVoice Clients' News
|
Company: United Cannabis Corp. (OTCQB: CNAB)
|
United Cannabis Corporation and Cannabinoid Research & Development Enter Business Partnership with Jamaica's Scientific Research Council and University of the West Indies, Mona, Jamaica
Initial Focus Will Be Research to Support Patent Applications and Pre-Clinical Trials for Prana Bio Medicinal Product Line
DENVER, CO / ACCESSWIRE / February 25, 2015 / United Cannabis Corporation (OTC: CNAB) (the “Company” or “United Cannabis”) today announced that it has entered into a Business Partnership with Cannabinoid Research & Development (“CRD”) and Jamaica’s Scientific Research Council, to establish a branded genetic database and conduct product analysis and preclinical studies of its entire Prana Bio Medicinal product line. The Partnership will collaborate with the University Of The West Indies, Mona (“UWI”) and have access to its staff and facilities, most notably the School of Medical Sciences, Clinical Trial Centre, and eight associated hospitals.
Continue Reading |
Other Small Cap News
|
Company: SANUWAVE Health, Inc. (OTCBB: SNWV)
|
SANUWAVE Receives U.S. Patent for Medical Treatment Systems That Select and Use the Proper Ancillary Interfaces and Specific Treatment Parameters for Electronic Treatment Devices
ALPHARETTA, Ga., Feb. 25, 2015 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) announced today the receipt of U.S. Pat. No. 8,961,441 from the U.S. Patent and Trademark Office entitled, "Medical Treatment System Including an Ancillary Medical Treatment Apparatus with an Associated Data Storage Medium."
"We believe this new patent provides excellent coverage for medical treatment systems that include electronic devices and auxiliary treatment interfaces with enhanced controls for identification and authentication of proper treatment components, and for providing specific treatment parameters based on the medical condition, targeted body part, tissue, or organ," commented Kevin A. Richardson, II, Chairman of the board of directors of SANUWAVE. "In view of its broad applicability to existing and future SANUWAVE devices and many types of modern medical systems, this patent is an important addition to our patent portfolio."
Continue Reading
|
Company: Event Cardio Group, Inc. (OTCQB: ECGI)
|
Event Cardio Group Inc. Engages Ceres Technologies for Engineering Production of FDA Cleared BreastCare DTS Device
NEW YORK, NY--(Marketwired - Feb 25, 2015) - Event Cardio Group, Inc. (OTCQB: ECGI), a medical device company, is pleased to announce it has contracted Ceres Technologies, based in Saugerties, New York, to engineer and manufacture BreastCare DTS™. Mechanical, electrical and chemical engineers at Ceres are completing design and execution plans for the first production units to be completed Mid-March.
An easy-to-use, FDA approved single-use device, BreastCare DTS™ is to be marketed as an adjunct to mammography and other procedures for the detection of breast cancer. The patented device consists of two soft, disposable pads that are lightweight and non-invasive, and are 98% accurate as an early detector of possible breast cancer.
Continue Reading |
Market News
|
By Paul Armentano: High Times
|
Congressman Pushes Attorney General to Reclassify Cannabis
Tennessee Congressman Steven Cohen is urging outgoing Attorney General Eric Holder to reclassify cannabis under federal law. Cohen, a Democrat, sent a letter to the Holder last week pressing him to remove the plant from its long-standing categorization as a Schedule I federally prohibited substance.
By definition, Schedule I substances must meet three specific criteria: “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and “a lack of accepted safety... under medical supervision.” Substances that do not meet all three criteria are required by law to be placed in some alternative schedule or removed from the Controlled Substances Act altogether (like alcohol and tobacco).
Holder has previously stated that he is open to debating the issue of rescheduling marijuana, telling news anchor Katie Couric in October that “whether or not marijuana is as serious a drug as is heroin... [is] certainly a question that we need to ask ourselves.” But he has also argued that this action ought to be taken by members of the US Congress, not via executive action. However, under federal law, the executive authority to reclassify controlled substances lies with the attorney general - a point that Congressman Cohen was quick to emphasize.
Continue Reading
|
By Matt Krantz: USA Today
|
7 Nasdaq stocks are still big bargains
Nasdaq is close to 5000 again. But fret not. Believe it or not - there are still stocks that are attractively priced.
There are seven stocks in the Nasdaq 100 index, including memory card maker SanDisk, biotech Gilead Sciences and entertainment company Viacom that look like barginas on multiple fronts based on the data. These stocks are rated "outperform" by analysts, still have upside before hitting their the 18-month price targets, have PEG ratios of less than 1.5, according to S&P Capital IQ, and are rated "attractive" or better by New Constructs.
Phew. Meeting all these standards is quite a feat - since it's getting harder to find stocks most people can agree on. The PEG ratio is a comparison of the price-to-earnings ratio based on expected earnings relative to the company's growth rate. Bargain hunting investors usually like to see PEG ratios of less than 1, but a PEG of 1.5 is pretty attractive in this market given the average PEG in the Nasdaq 100 has soared to nearly 3. The Nasdaq 100 is a collection of the 100 most valuable non-financial stocks in the Nasdaq.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
